UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 607

Sortiert nach

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial

Journal of clinical oncology, 2022-12, Vol.40 (35), p.4071-4082

2022

Volltextzugriff (PDF)

No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study

Annals of oncology, 2015-06, Vol.26 (6), p.1149-1154

2015

Volltextzugriff (PDF)

Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up

Breast (Edinburgh), 2021-10, Vol.59, p.294-300

2021

Volltextzugriff (PDF)

Hypoxia, Snail and incomplete epithelial-mesenchymal transition in breast cancer

British journal of cancer, 2009-11, Vol.101 (10), p.1769-1781

2009

Volltextzugriff (PDF)

Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer

JNCI : Journal of the National Cancer Institute, 2009-03, Vol.101 (5), p.341-349

2009

Volltextzugriff (PDF)

Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial

British journal of cancer, 2011-05, Vol.104 (11), p.1762-1769

2011

Volltextzugriff (PDF)

Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study

European journal of cancer (1990), 2006-05, Vol.42 (7), p.895-904

2006

Volltextzugriff (PDF)

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer

British journal of cancer, 2016-02, Vol.114 (3), p.248-255

2016

Volltextzugriff (PDF)

Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial

British journal of cancer, 2011-03, Vol.104 (6), p.899-902

2011

Volltextzugriff (PDF)

Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up

Acta oncologica, 2024-07, Vol.63 (1), p.535-541

2024

Volltextzugriff (PDF)

Coronary Heart Disease Mortality After 5 Years of Adjuvant Tamoxifen Therapy: Results from a Randomized Trial

JNCI : Journal of the National Cancer Institute, 2005-11, Vol.97 (21), p.1609-1610

2005

Volltextzugriff (PDF)

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer

Annals of oncology, 2013-08, Vol.24 (8), p.1994-1999

2013

Volltextzugriff (PDF)

Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy

Breast (Edinburgh), 2023-10, Vol.71, p.63-68

2023

Volltextzugriff (PDF)

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer

JNCI : Journal of the National Cancer Institute, 2018-07, Vol.110 (7), p.726-733

2018

Volltextzugriff (PDF)

Effects of adjuvant tamoxifen over three decades on breast cancerefree and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial

European journal of cancer (1990), 2019-03, Vol.110, p.53

2019

Volltextzugriff (PDF)

Applying the Nottingham Prognostic Index to a Swedish breast cancer population

Breast cancer research and treatment, 1999, Vol.53 (1), p.1-8

1999

Volltextzugriff (PDF)

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature

International journal of cancer, 2022-06, Vol.150 (12), p.2072-2082

2022

Volltextzugriff (PDF)

ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer

Clinical cancer research, 2016-03, Vol.22 (6), p.1421-1431

2016

Volltextzugriff (PDF)

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit

Breast cancer research and treatment, 2013-01, Vol.137 (2), p.397-406

2013

Volltextzugriff (PDF)

PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer

Clinical cancer research, 2007-06, Vol.13 (12), p.3577-3584

2007

Volltextzugriff (PDF)

Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial

JAMA network open, 2021-06, Vol.4 (6), p.e2114904-e2114904

2021

Volltextzugriff (PDF)

Effects of adjuvant tamoxifen over three decades on breast cancer–free and distant recurrence–free interval among premenopausal women with oestrogen receptor–positive breast cancer randomised in the Swedish SBII:2pre trial

European journal of cancer (1990), 2019-03, Vol.110, p.53-61

2019

Volltextzugriff (PDF)

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

JAMA oncology, 2017-11, Vol.3 (11), p.1503

2017

Volltextzugriff (PDF)

PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer

Journal of cancer research and clinical oncology, 2019-03, Vol.145 (3), p.599-607

2019

Volltextzugriff (PDF)

The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials

Breast cancer research : BCR, 2013-01, Vol.15 (5), p.R96-R96, Article R96

2013

Volltextzugriff (PDF)

1 – 25 von 607

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(570)
Mit Volltextzugriff
(549)

Publikationsform

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial

No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study

Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up

Hypoxia, Snail and incomplete epithelial-mesenchymal transition in breast cancer

Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer

Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial

Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer

Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial

Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up

Coronary Heart Disease Mortality After 5 Years of Adjuvant Tamoxifen Therapy: Results from a Randomized Trial

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer

Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer

Effects of adjuvant tamoxifen over three decades on breast cancerefree and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial

Applying the Nottingham Prognostic Index to a Swedish breast cancer population

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature

ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit

PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer

Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial

Effects of adjuvant tamoxifen over three decades on breast cancer–free and distant recurrence–free interval among premenopausal women with oestrogen receptor–positive breast cancer randomised in the Swedish SBII:2pre trial

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer

The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials

Suchergebnisse filtern